Q-omics provides the consensus-scored RPL10AP1 profile across patient tissues and cancer cell-line models. RPL10AP1 expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, RPL10AP1 is differentially expressed in 8, with the highest sampling consensus in COAD. Additionally, RPL10AP1 RNA expression shows 9,667 significant gene co-expression associations, with the highest sampling consensus in LAML. Together, these results highlight KIRP, COAD, and LAML as cancer lineages where RPL10AP1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPL10AP1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPL10AP1 survival associations across molecular data types. RPL10AP1 RNA expression shows survival associations in the most cancer types (19). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPL10AP1 RNA expression–survival associations across cancer types. High RPL10AP1 expression shows unfavorable associations in ACC, THCA and LUSC, but favorable associations in KIRP, MESO and LAML. The KIRP Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for RPL10AP1 RNA expression.
This table summarizes RPL10AP1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for RPL10AP1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPL10AP1 shows lower tumor expression in KICH, STAD and BRCA and higher tumor expression in COAD, HNSC and LIHC. The COAD box plot shows higher RPL10AP1 RNA expression in tumor versus normal tissue (log2 FC = +0.692, t-test p < 0.001).
This table shows molecular features associated with RPL10AP1 in patient tissues and cancer cell lines. In patient samples, RPL10AP1 shows the broadest associations at the RNA and protein expression levels, with LAML recurring as the lineage with the largest associated feature set.
